Checkpoint Inhibitors in Malignant Pleural Mesothelioma
0 Visualizzazioni
• 07/02/23
0
0
Incorporare
administrator
Iscritti
Mark Socinski, MD; Mary Jo Fidler, MD; Roy Herbst, MD, PhD; Geoffrey Oxnard, MD; and Naiyer Rizvi, MD discuss the potential for checkpoint inhibitors, such as pembrolizumab, for malignant mesothelioma. Also discussed is the importance of trials that can be done in the community setting.
Mostra di più
Commenti su Facebook
SORT BY-
I migliori commenti
-
Ultimi commenti